[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Legend Biotech Corp ADR (LEGN)

Legend Biotech Corp ADR (LEGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,948,833
  • Shares Outstanding, K 185,740
  • Annual Sales, $ 1,029 M
  • Annual Income, $ -296,800 K
  • EBIT $ -65 M
  • EBITDA $ -36 M
  • 60-Month Beta 0.37
  • Price/Sales 4.08
  • Price/Cash Flow N/A
  • Price/Book 3.41

Options Overview Details

View History
  • Implied Volatility 56.22% (-8.02%)
  • Historical Volatility 71.91%
  • IV Percentile 28%
  • IV Rank 16.66%
  • IV High 119.66% on 03/19/26
  • IV Low 43.54% on 11/14/25
  • Expected Move (DTE 28) 2.27 (10.40%)
  • Put/Call Vol Ratio 0.38
  • Today's Volume 2,631
  • Volume Avg (30-Day) 1,612
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 34,620
  • Open Int (30-Day) 28,359
  • Expected Range 19.55 to 24.09

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $0.06
  • Number of Estimates 6
  • High Estimate $0.16
  • Low Estimate $-0.20
  • Prior Year $-0.11
  • Growth Rate Est. (year over year) +154.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.33 +19.04%
on 07/31/26
24.05 -9.27%
on 07/23/26
-1.72 (-7.31%)
since 07/21/26
3-Month
18.33 +19.04%
on 07/31/26
37.50 -41.81%
on 06/03/26
-6.17 (-22.04%)
since 05/21/26
52-Week
16.24 +34.36%
on 02/04/26
37.50 -41.81%
on 06/03/26
-13.71 (-38.59%)
since 08/21/25

Most Recent Stories

More News
Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights

CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 50% versus second quarter of 2025 to approximately $657 million Expanded CARVYKTI ® availability to 348 global sites and...

LEGN : 21.82 (+2.63%)
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results

BRIDGEWATER N.J., July 28, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 a.m....

LEGN : 21.82 (+2.63%)
Legend Biotech Announces CEO Transition

Ying Huang, Ph.D., steps down as Chief Executive Officer and member of the Board of Directors; will remain as an advisor through August to support a smooth transition Alan Bash, current President of...

LEGN : 21.82 (+2.63%)
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors

SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the development of targeted genetic...

CLDI : 1.3400 (unch)
LEGN : 21.82 (+2.63%)
RARE : 25.83 (+2.01%)
Legend Biotech Corporation Announces Pricing of Public Offering

BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced the pricing...

LEGN : 21.82 (+2.63%)
Legend Biotech Corporation Announces Proposed Public Offering 

BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced that it has...

LEGN : 21.82 (+2.63%)
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1 study Single infusion of LB2501 generated dose-dependent...

LEGN : 21.82 (+2.63%)
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

 Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1 study Single infusion of LB2501 generated dose-dependent...

LEGN : 21.82 (+2.63%)
Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)

Promising Phase 1 data for LB2501, a potential first ‑ in ‑ class CD19/CD20 dual ‑ targeting in vivo CAR-T therapy, as an off-the-shelf, single-infusion treatment for B ‑ cell malignancies...

LEGN : 21.82 (+2.63%)
Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026

LB2102 demonstrated a manageable safety profile and encouraging clinical activity in solid tumors among heavily pretreated patients  Responses observed at higher dose levels of LB2102 with an ORR of...

LEGN : 21.82 (+2.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Legend Biotech Corporation is a clinical-stage biopharmaceutical company. It engaged in the discovery and development of novel cell therapies for oncology and other indications. The company's lead product consist LCAR-B38M/JNJ-4528, which are in clinical stage. Legend Biotech Corporation is based in...

See More

Key Turning Points

3rd Resistance Point 24.69
2nd Resistance Point 23.97
1st Resistance Point 22.61
Last Price 21.82
1st Support Level 20.53
2nd Support Level 19.81
3rd Support Level 18.45

See More

52-Week High 37.50
Fibonacci 61.8% 29.38
Fibonacci 50% 26.87
Fibonacci 38.2% 24.36
Last Price 21.82
52-Week Low 16.24

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.